文献速递基础与转化研究临床试验与 GCP

iPSC来源神经祖细胞治疗亚急性脊髓损伤的1期试验及长期随访

An iPSC-derived neural progenitor cell therapy for subacute spinal cord injury: a phase 1 trial with long-term follow-up.
PubMed 文献 · Nat Med · 2026-07-21

这是一项首次人体、开放标签的1期研究,在4例亚急性颈段完全性脊髓损伤患者中移植iPSC来源神经干/祖细胞。主要安全终点达到,随访2-4年无肿瘤形成或移植物相关不良事件,影像学见移植物部位稳定。探索性疗效显示运动评分中位改善13分,2例AIS分级改善,数值上大于注册队列的自然恢复。

要点

  • iPSC来源NS/PC移植在4例亚急性颈段完全性SCI中短期免疫抑制下可行且安全
  • 随访2-4年无肿瘤形成或移植物相关不良事件,影像学移植物部位稳定
  • 运动评分中位改善13分,2例AIS分级改善,数值上大于注册队列自然恢复

核心结论

  • 人iPSC来源NS/PC移植入损伤脊髓在短期免疫抑制下可行且安全,支持进一步临床评估。

研究设计与样本

  • 首次人体、开放标签1期研究,纳入4例亚急性颈段完全性脊髓损伤患者。
  • 主要终点为安全性,探索性疗效作为次要终点评估。

主要发现

  • 随访2-4年无肿瘤形成或移植物相关不良事件,影像学见移植物部位稳定。
  • 从基线(伤后2周)至第52周,ISNCSCI运动评分中位改善13分(范围10-40)。
  • 2例患者AIS分级改善(A→C和A→D),改善数值上大于注册队列的自然恢复。

临床怎么用

  • 该结果提示iPSC-NS/PC移植可作为亚急性完全性颈段SCI的潜在研究性治疗方向。
  • 目前证据限于1期小样本,尚不能常规用于临床,需进一步临床试验验证。

局限性

  • 开放标签、无对照、样本量仅4例,探索性疗效需谨慎解读。
  • 疗效比较基于注册队列的自然恢复数据,非随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Spinal cord injury (SCI) causes irreversible motor and sensory deficits, and no therapy currently restores the damaged neural circuitry. Previous work has shown that transplantation of induced pluripotent stem cell (iPSC)-derived neural stem/progenitor cells (NS/PCs) restored motor function in preclinical models of subacute SCI; however, the safety of this approach in humans remains unknown. Here we report results from a first-in-human, open-label study of iPSC-NS/PC transplantation in four patients with subacute cervical complete SCI. The primary safety end point was achieved, with no tumor formation or graft-related adverse events observed during 2-4 years of follow-up and stable graft sites on imaging. Exploratory efficacy was assessed as a secondary end point. Median improvement in the International Standards for Neurological Classification of Spinal Cord Injury motor score from baseline (2 weeks after injury) to week 52 was 13 points (range 10-40), with two patients improving in American Spinal Injury Association Impairment Scale (grade A → C and A → D). These gains were numerically greater than spontaneous recovery observed in a registry-based cohort. This study provides clinical evidence that transplantation of human iPSC-NS/PCs into the injured spinal cord is feasible and safe under short-term immunosuppression, with findings supporting further clinical evaluation. The trial is registered at UMIN000035074 , UMIN000050104 and jRCTa031190228 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Sugai K, Tsuji O, Fujiyoshi K, et al. An iPSC-derived neural progenitor cell therapy for subacute spinal cord injury: a phase 1 trial with long-term follow-up. Nat Med. 2026. PMID: 42481854. doi:10.1038/s41591-026-04549-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。